
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
A study in the May 10 online edition of the American Cancer Society journal Cancer shows that the number of HIV-positive people with Kaposi's sarcoma, a rare cancer that was once common among early AIDS patients, has declined sharply since the arrival of highly active antiretroviral therapy. The annual incidence of the cancer among HIV-positive adults fell 39% between 1994 and 2003, according to a multicenter study of nearly 10,000 European HIV patients. The researchers say KS was the least likely to be reported by HAART users taking anti-HIV drugs the longest or in those who achieved high CD4-cell counts through antiretroviral therapy, which boosts natural defenses against the disease. 'Patients who start HAART should experience a reduction in the risk of Kaposi's sarcoma if the CD4 count starts to rise,' the researchers say. The study was the first large-scale research project to conclusively prove a link between combination anti-HIV therapy and the decline in cases of KS.
From our Sponsors
Most Popular
Plus: Featured Video